TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug …

[Read more...] about Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

 Akari Will Exclusively Partner with Industry Leader WuXi XDC For This Key IND-enabling Work Tampa, FL and London – December 23, 2025 – Akari …

[Read more...] about Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Access the Akari CEO Corner here BOSTON and LONDON – November 25, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing …

[Read more...] about Akari Therapeutics Announces Release of the Next CEO Corner Segment